Business
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
Bionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer’s DiseaseBased on the
About this update from Neuphoria Therapeutics Inc.
[{"type":"text","content":"Bionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer’s DiseaseBased on the learnings from Bionomics’ candidate BNC375, additional candidates have been developed with improved drug like and pharmacological properties that are currently in Phase 1 safety, tolerability, pharmacokinetics and biomarker studies ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced an update on the company’s α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) collaboration with MSD (known as Merck & Co., Inc., Rahway NJ, USA in the US and Canada). Data for MK-4334, a novel clinical candidate developed by MSD and derived from Bionomics’ original α7 nAChR PAM candidate (BNC375), was recently presented at the Society for Chemical Industry (SCI) and Royal Society of Chemistry (RSC) 22nd Medicinal Chemistry Symposium, held in Cambridge, UK, September 10-13, 2023. “Bionomics has a long-standing collaboration with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders that address the limitations seen with nAChR agonists, such as lack of selectivity against related ligand-gated ion channels, desensitization of the receptor with sustained exposure, and an inverted U-shaped dose response function,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. “We are excited to see the progress being made in our collaboration with MSD.” The original lead molecule BNC375, a Type I α7 nAChR PAM, showed a robust and sustained dose-dependent efficacy over a broad dose range and across multiple cognitive animal models. MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375. In addition to Phase 1 safety, tolerability and clinical pharmacokinetics studies, clinical biomarker studies are ongoing to further evaluate the pharmacological response of α7 nAChR PAMs in humans. Under the 2014...